CEL-SCI Corp. (CVM) Reports on Work Conducted on LEAPS Vaccine Technology
More News related to CVM
- CEL-SCI Announces Start of First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine
- Is Amendment of Previously Filed Paperwork a Sign That CEL-SCI is Expecting Something Big?
- Morning Movers 11/09: EWBC, CVM, REV, CGEN, RSH Higher; CHDX, SRZ, GTN, RPRX, VSR Lower
- CEL-SCI Corp. (CVM) Reports on Work Conducted on LEAPS Vaccine Technology
- CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response
CEL-SCI Corporation (AMEX: CVM) announced today that Dr. Kenneth S. Rosenthal, Professor of Immunology and Microbiology of Northeastern Ohio Universities College of Medicine and Pharmacy, reported on work conducted in collaboration with scientists at the Cleveland Clinic and CEL-SCI on CEL-SCI's LEAPS vaccine technology. The data was presented at the 7th GTCbio Vaccine: "All Things Considered" Conference in Crystal City, Virginia.
Working with LEAPS vaccines for herpes simplex virus, HIV, rheumatoid arthritis and most recently, H1N1 influenza, the scientists' studies show that LEAPS peptide immunogens can convert precursor cells from mouse or humans to become dendritic cells (DC), the cell that directs the subsequent immune response. These DCs produce interleukin 12 (IL12p70), but without production of the pro-inflammatory cytokines that promote symptoms of a cytokine storm, such as tumor necrosis factor alpha or interleukin 1. Immunization with a LEAPS-immunogen for herpes simplex virus activates a protective T cell immune response against the virus in mice while a LEAPS-immunogen for treatment of rheumatoid arthritis (CEL-2000) reduces the production of the pro-inflammatory cytokines to block the progression of disease in mouse models of rheumatoid arthritis.
Geert Kersten, CEO of CEL-SCI Corporation said: "We feel that this new data is encouraging and supportive of our H1N1 treatment for hospitalized patients where the goal is to produce a specific anti H1N1 immune response that will steer the immune system towards protection and away from a cytokine storm which may be responsible for many patients' deaths."
CEL-SCI's L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology allows the Company to direct an immune response against specific disease epitopes.
Related Categories
Corporate NewsStocks Mentioned
+0.08Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
